Cargando…
Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells
Increasing evidence highlighted the role of cancer stem cells (CSCs) in the development of tumor resistance to therapy, particularly in glioblastoma (GBM). Therefore, the development of new therapies, specifically directed against GBM CSCs, constitutes an important research avenue. Considering the e...
Autores principales: | Angeletti, Francesca, Fossati, Gianluca, Pattarozzi, Alessandra, Würth, Roberto, Solari, Agnese, Daga, Antonio, Masiello, Irene, Barbieri, Federica, Florio, Tullio, Comincini, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081386/ https://www.ncbi.nlm.nih.gov/pubmed/27833530 http://dx.doi.org/10.3389/fnmol.2016.00107 |
Ejemplares similares
-
Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage
por: Pawelec, Paulina, et al.
Publicado: (2022) -
Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
por: Celesia, Adriana, et al.
Publicado: (2023) -
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
por: Celesia, Adriana, et al.
Publicado: (2022) -
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
por: Di Martile, Marta, et al.
Publicado: (2018) -
Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells
por: Corsaro, Alessandro, et al.
Publicado: (2016)